within Pharmacolibrary.Drugs.ATC.H;

model H01CC03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.46,
    Cl             = 0.00018,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.167,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0205,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.052,
    k12             = 35.3,
    k21             = 35.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01CC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Elagolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used primarily for the management of moderate to severe pain associated with endometriosis in women. It is approved by the FDA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy premenopausal women following oral administration.</p><h4>References</h4><ol><li><p>Shebley, M, et al., &amp; Mostafa, NM (2020). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. <i>Clinical pharmacokinetics</i> 59(3) 297–309. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00840-7&quot;>10.1007/s40262-019-00840-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31749075/&quot;>https://pubmed.ncbi.nlm.nih.gov/31749075</a></p></li><li><p>Nader, A, et al., &amp; Shebley, M (2022). Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. <i>Clinical and translational science</i> 15(5) 1269–1280. DOI:<a href=&quot;https://doi.org/10.1111/cts.13247&quot;>10.1111/cts.13247</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35137535/&quot;>https://pubmed.ncbi.nlm.nih.gov/35137535</a></p></li><li><p>Nader, A, et al., &amp; Shebley, M (2021). Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy. <i>Clinical pharmacokinetics</i> 60(1) 133–143. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00921-y&quot;>10.1007/s40262-020-00921-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32696440/&quot;>https://pubmed.ncbi.nlm.nih.gov/32696440</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01CC03;
